Transaction #24079 · Form 4 · 0001493152-25-028758
Lantern Pharma Inc. · Stock award · Stock Option (Right to Buy)
Lantern Pharma Inc. · Transacted December 18, 2025 · Filed December 22, 2025
What does this filing report?
An SEC Form 4 filing for Lantern Pharma Inc. records a stock award involving Stock Option (Right to Buy) on December 18, 2025. The reported quantity was 10,000. The filing date is December 22, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- Lantern Pharma Inc.
- Company CIK
- 0001763950
- Security type
- Derivative
- Acquisition type
- Stock award · Code A
- Quantity acquired
- 10,000
- Reported price
- 0
- Reference value
- 0
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 10,000
- Ownership description
- Not reported
- SEC acceptance time
- Dec 22, 2025, 4:05 PM EST
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- Bhatia Kishor G. ↗
Chief Scientific Officer
CIK 0001812638
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
This transaction is not mapped to a specific company listing.
Derivative terms
- Underlying security
- Common Stock
- Underlying quantity
- 10,000
- Conversion / exercise price
- 3.24
- Exercise date
- Not reported
- Expiration date
- December 17, 2035
Filing footnotes & remarks
- F1
- The Options are granted under the Lantern Pharma Inc. Amended and Restated 2018 Stock Incentive Plan. The Options shall vest and first become exercisable in equal monthly increments over a 24-month period commencing January 18, 2026.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.